Chronic myeloid leukemia (CML) is characterized by the constitutively active tyrosine kinase BCR::ABL1, and standard therapy is treatment with tyrosine kinase inhibitors (TKI). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.